# A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

> **NCT05257083** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Stichting European Myeloma Network** · enrollment: 759 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Bortezomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Cilta-cel
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT05257083
- **Lead sponsor:** Stichting European Myeloma Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-10
- **Primary completion:** 2033-06
- **Final completion:** 2040-08
- **Target enrollment:** 759 (ACTUAL)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05257083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05257083, "A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05257083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*